Supplementary Figures from Discovery of Podofilox As a Potent Cgamp–sting Signaling Enhancer with Antitumor Activity

Jing Han,Shuiqing Hu,Yawei Hu,Yifang Xu,Yanfei Hou,Yinlong Yang,Huili Su,Zhengyin Zhang,Peng Liu,Xuxu Sun,Conggang Zhang

DOI: https://doi.org/10.1158/2326-6066.22627016

2023-01-01

Abstract:Supplementary Figures S1 to S9 with Legends

What problem does this paper attempt to address?

Supplementary Figure Legends from Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells

Rajat Bhattacharya,Xiang-Cang Ye,Rui Wang,Xia Ling,Madonna McManus,Fan,Delphine Boulbes,Lee M. Ellis

DOI: https://doi.org/10.1158/0008-5472.22407995.v1

2023-01-01

Abstract:Legends for Supplementary Figures S1-S12.
Supplementary Figure Legends and Supplementary Figures 1 Through 4 from A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies

Xiaohui Fan,Randall J. Brezski,Hui Deng,Pooja Dhupkar,Yun Q. Shi,Anneliese Gonzalez,Songlin Zhang,Michael A. Rycyzyn,William R. Strohl,Robert E. Jordan,Ningyan Zhang,Zhiqiang An

DOI: https://doi.org/10.1158/1535-7163.22501711

2023-01-01

Abstract:Figure S1: IdeS expression in BT474 breast cancer cells Figure S2: Detection of MMPs in cancer cell lysates and culture supernatant Figure S3: scIgG-T was not in the SKBR-3 cell culture medium Figure S4: Detection of immune cells infiltration in mice by flow cytometry.
Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Jiahui Mou,Meijun Huang,Feifei Wang,Xiaoding Xu,Hanqi Xie,Henglei Lu,Mingyang Li,Yu Li,Weiwen Kong,Jing Chen,Ying Xiao,Yiding Chen,Chaochen Wang,Jin Ren

DOI: https://doi.org/10.1158/1541-7786.22527890

2023-01-01

Abstract:Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis
Discovery of podofilox as a potent cGAMP–STING signaling enhancer with antitumor activity

Jing Han,Shuiqing Hu,Yawei Hu,Yifang Xu,Yanfei Hou,Yinlong Yang,Huili Su,Zhengyin Zhang,Peng Liu,Xuxu Sun,Conggang Zhang

DOI: https://doi.org/10.1158/2326-6066.cir-22-0483

IF: 10.1

2023-03-17

Cancer Immunology Research

Abstract:Cyclic GMP–AMP (cGAMP) is a second messenger that activates the stimulator of interferon genes (STING) innate immune pathway to induce the expression of type I interferons (IFNs) and other cytokines. Pharmacological activation of STING is considered a potent therapeutic strategy in cancer. In this study, we employed a cell-based phenotypic screen and identified podophyllotoxin (podofilox), a microtubule destabilizer, as a robust enhancer of the cGAMP–STING signaling pathway. We found that podofilox enhanced the cGAMP-mediated immune response by increasing STING-containing membrane puncta and the extent of STING oligomerization. Furthermore, podofilox changed the trafficking pattern of STING and delayed trafficking-mediated STING degradation. Importantly, the combination of cGAMP and podofilox had profound antitumor effects on mice by activating the immune response through host STING signaling. Together, these data provide insights into the regulation of cGAMP–STING pathway activation and demonstrate what we believe to be a novel approach for modulating this pathway and thereby promoting antitumor immunity.

oncology,immunology
Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Jeff Hsu,Colin Chong,Jeffrey Serrill,Levina Goon,Joan Balayan,Eric N. Johnson,Grachelle Lorenzana,Sharon Wu,Kevin G. Leong,Theodore J. Yun,Yong Wang,Faming Jiang,Lynne Bannen,Peter Lamb,Wei Xu,Peiwen Yu

DOI: https://doi.org/10.1158/1535-7163.22523460

2023-01-01

Abstract:Supplementary Figures and Tables with adjoining Legends
Supplementary Figure Legend from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Junying Zeng,Sharad Sharma,Yong‐Qing Zhou,Hang‐Ping Yao,Xing Hu,Ruiwen Zhang,Ming-Hai Wang

DOI: https://doi.org/10.1158/1535-7163.22503690

2023-01-01

Abstract:PDF - 71K, Legends for Supplementary Figures 1 through 5.
Supplemental Figure Legends from Notch Pathway Inhibition Using PF-03084014, a Γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer

Di Cui,Jinlu Dai,Jill M. Keller,Atsushi Mizokami,Shujie Xia,Evan T. Keller

DOI: https://doi.org/10.1158/1078-0432.22460979.v1

2023-01-01

Abstract:Supplemental Figure Legends
Legend for Supplementary Figures from Dual PI3K/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma

Tongxin Liu,Quanquan Sun,Qi Li,Hua Yang,Yuqin Zhang,Rong Wang,Xiaoshan Lin,Dong Xiao,Yawei Yuan,Longhua Chen,Wei Wang

DOI: https://doi.org/10.1158/1535-7163.22502823

2023-01-01

Abstract:Supplementary Figure legends
Supplementary Figure Legends from EpCAM Inhibition Sensitizes Chemoresistant Leukemia to Immune Surveillance

Xin Zheng,Xiaolei Fan,Binqing Fu,Ming–Hua Zheng,Aimei Zhang,Kai Zhong,Jun Yan,Rui Sun,Zhigang Tian,Wei H

DOI: https://doi.org/10.1158/0008-5472.22414839.v1

2023-01-01

Abstract:Supplementary Figure 1-6 legends
Supplementary Figures 1-2 from Inhibition of Mitogen-Elicited Signal Transduction and Growth in Prostate Cancer with a Small Peptide Derived from the Functional Domain of DOC-2/DAB2 Delivered by a Unique Vehicle

Jian Zhou,Jinhai Fan,Jer-Tsong Hsieh

DOI: https://doi.org/10.1158/0008-5472.22365053.v1

2023-01-01

Abstract:Supplementary Figures 1-2 from Inhibition of Mitogen-Elicited Signal Transduction and Growth in Prostate Cancer with a Small Peptide Derived from the Functional Domain of DOC-2/DAB2 Delivered by a Unique Vehicle
Supplementary Figure Legends from Accelerated Tumor Growth Mediated by Sublytic Levels of Antibody-Induced Complement Activation is Associated with Activation of the PI3K/AKT Survival Pathway

Xiaohong Wu,Govind Ragupathi,Katherine S. Panageas,Feng Hong,Philip O. Livingston

DOI: https://doi.org/10.1158/1078-0432.22446662

2023-01-01

Abstract:Legend for supplementary figures - PDF file 62K, Supplementary Figure Legend
Supplementary Figure Legends from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth

K. Mark Parnell,Jason M. Foulks,Rebecca N. Nix,Adrianne Clifford,Jeremy Bullough,Bin Luo,Anna V. Senina,David Vollmer,Jihua Liu,Virgil McCarthy,Yong Xu,Michael Saunders,Xiaohui Liu,Scott Pearce,Kevin B. Wright,Marc O’Reilly,Michael V. McCullar,Koc-Kan Ho,Steven B. Kanner

DOI: https://doi.org/10.1158/1535-7163.22499760.v1

2023-01-01

Abstract:Supplementary Figure Legends - PDF file 41K, Legends for supplemental figures 1-4
Supplementary Figures Legends from Qa-1<sup>b</sup> Modulates Resistance to Anti–PD-1 Immune Checkpoint Blockade in Tumors with Defects in Antigen Processing

Xiao Zhang,Erich Sabio,Chirag Krishna,Xiaojing Ma,Jingming Wang,Hui Jiang,Jonathan J. Havel,Timothy A. Chan

DOI: https://doi.org/10.1158/1541-7786.22526916.v1

2023-01-01

Abstract:Supplemental Figure Legends 1-4
Supplementary Methods, Figures 1-15 from SM-164: A Novel, Bivalent Smac Mimetic That Induces Apoptosis and Tumor Regression by Concurrent Removal of the Blockade of Ciap-1/2 and XIAP

Jianfeng Lu,Longchuan Bai,Haiying Sun,Zaneta Nikolovska-Coleska,Donna McEachern,Su Qiu,Rebecca S. Miller,Han Yi,Sanjeev Shangary,Yi Sun,Jennifer L. Meagher,Jeanne A. Stuckey,Shaomeng Wang

DOI: https://doi.org/10.1158/0008-5472.22375851

2023-01-01

Abstract:Supplementary Methods, Figures 1-15 from SM-164: A Novel, Bivalent Smac Mimetic That Induces Apoptosis and Tumor Regression by Concurrent Removal of the Blockade of cIAP-1/2 and XIAP
Supplementary Figures from Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody–Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function

Rui Jin,Liang Liu,Yun Xing,Tao Meng,Li Ma,Jinpeng Pei,Ying Cong,Xuesai Zhang,Zhiqiang Ren,Xin Wang,Jingkang Shen,Ker Yu

DOI: https://doi.org/10.1158/1535-7163.22519333

2023-01-01

Abstract:Supplementary Figures and Tables
Supplementary Fig. 5 from Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment

Leonard C. Rogers,Jeff C. Kremer,Caitlyn B. Brashears,Zongtao Lin,Zhixian Hu,Alliny C.S. Bastos,Adriana Baker,Nicole Fettig,Dong Zhou,Kooresh I. Shoghi,Carina A. Dehner,John S.A. Chrisinger,John S. Bomalaski,Benjamin A. Garcia,Toshinao Oyama,Eileen P. White,Brian A. Van Tine

DOI: https://doi.org/10.1158/1078-0432.23952333.v1

2023-01-01

Abstract:Supplemental Figure 5. Evidence against other possible growth support mechanisms and MEF toxicity.
Supplementary Figure 5 from PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer

Amanda Herzog,Yansong Bian,Robert Vander Broek,Bradford Hall,Jamie Coupar,Hui Cheng,Anastasia L. Sowers,John D. Cook,James B. Mitchell,Zhong Chen,Ashok B. Kulkarni,Carter Van Waes

DOI: https://doi.org/10.1158/1078-0432.22445265

2023-01-01

Abstract:PDF file - 1957K, Treatment in UM-SCC xenograft and Tgfbr1/Pten KO mice.
Supplementary Figure 7 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Annette O. Walter,Robert Tjin Tham Sjin,Henry J. Haringsma,Kadoaki Ohashi,Jing Sun,Kwangho Lee,Aleksandr Dubrovskiy,Matthew Labenski,Zhendong Zhu,Zhigang Wang,Michael Sheets,Thia St Martin,Russell Karp,Dan van Kalken,Prasoon Chaturvedi,Deqiang Niu,Mariana Nacht,Russell C. Petter,William Westlin,Kevin Lin,Sarah Jaw-Tsai,Mitch Raponi,Terry Van Dyke,Jeff Etter,Zoe Weaver,William Pao,Juswinder Singh,Andrew D. Simmons,Thomas C. Harding,Andrew Allen

DOI: https://doi.org/10.1158/2159-8290.22530291.v1

2023-01-01

Abstract:Supplementary Figure 7 - PDF file 352K, H&E and immunohistochemical (Ki67) staining of tumors derived from EGFR mutant GEM models
Supplemental Figure Legends from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors

Enxiu Wang,Liang-Chuan Wang,Ching-Yi Tsai,Vijay Bhoj,Zack Gershenson,Edmund K. Moon,Kheng Newick,Jing Sun,Albert Lo,Timothy Baradet,Michael D. Feldman,David M. Barrett,Ellen Puré,Steven Μ. Albelda,Michael C. Milone

DOI: https://doi.org/10.1158/2326-6066.22538600.v1

2023-01-01

Abstract:Figure legends for supplemental data.
Supplementary Figures 1-9 from Combined Treatment of Pancreatic Cancer with Mithramycin A and Tolfenamic Acid Promotes Sp1 Degradation and Synergistic Antitumor Activity

Zhiliang Jia,Yong Gao,Liwei Wang,Qiang Li,Jun Zhang,Xiangdong Le,Daoyan Wei,James C. Yao,David Z. Chang,Suyun Huang,Keping Xie

DOI: https://doi.org/10.1158/0008-5472.22383920.v1

2023-01-01

Abstract:Supplementary Figures 1-9 from Combined Treatment of Pancreatic Cancer with Mithramycin A and Tolfenamic Acid Promotes Sp1 Degradation and Synergistic Antitumor Activity

Supplementary Figures from Discovery of Podofilox As a Potent Cgamp–sting Signaling Enhancer with Antitumor Activity

Supplementary Figure Legends from Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells

Supplementary Figure Legends and Supplementary Figures 1 Through 4 from A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies

Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Discovery of podofilox as a potent cGAMP–STING signaling enhancer with antitumor activity

Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Supplementary Figure Legend from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplemental Figure Legends from Notch Pathway Inhibition Using PF-03084014, a Γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer

Legend for Supplementary Figures from Dual PI3K/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma

Supplementary Figure Legends from EpCAM Inhibition Sensitizes Chemoresistant Leukemia to Immune Surveillance

Supplementary Figures 1-2 from Inhibition of Mitogen-Elicited Signal Transduction and Growth in Prostate Cancer with a Small Peptide Derived from the Functional Domain of DOC-2/DAB2 Delivered by a Unique Vehicle

Supplementary Figure Legends from Accelerated Tumor Growth Mediated by Sublytic Levels of Antibody-Induced Complement Activation is Associated with Activation of the PI3K/AKT Survival Pathway

Supplementary Figure Legends from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth

Supplementary Figures Legends from Qa-1&lt;sup&gt;b&lt;/sup&gt; Modulates Resistance to Anti–PD-1 Immune Checkpoint Blockade in Tumors with Defects in Antigen Processing

Supplementary Methods, Figures 1-15 from SM-164: A Novel, Bivalent Smac Mimetic That Induces Apoptosis and Tumor Regression by Concurrent Removal of the Blockade of Ciap-1/2 and XIAP

Supplementary Figures from Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody–Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function

Supplementary Fig. 5 from Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment

Supplementary Figure 5 from PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer

Supplementary Figure 7 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplemental Figure Legends from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors

Supplementary Figures 1-9 from Combined Treatment of Pancreatic Cancer with Mithramycin A and Tolfenamic Acid Promotes Sp1 Degradation and Synergistic Antitumor Activity

Supplementary Figures Legends from Qa-1<sup>b</sup> Modulates Resistance to Anti–PD-1 Immune Checkpoint Blockade in Tumors with Defects in Antigen Processing